| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing mice.
|
Clin Cancer Res
|
2003
|
1.13
|
|
2
|
Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts.
|
Blood
|
2003
|
0.99
|
|
3
|
Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials.
|
J Natl Cancer Inst
|
2013
|
0.99
|
|
4
|
Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma.
|
Br J Haematol
|
2014
|
0.97
|
|
5
|
Disulfide cross-linked micelles for the targeted delivery of vincristine to B-cell lymphoma.
|
Mol Pharm
|
2012
|
0.92
|
|
6
|
High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody.
|
Clin Cancer Res
|
2005
|
0.92
|
|
7
|
Targeting CD22 in B-cell malignancies: current status and clinical outlook.
|
BioDrugs
|
2013
|
0.87
|
|
8
|
Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model.
|
Clin Cancer Res
|
2010
|
0.84
|
|
9
|
Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia.
|
Leuk Res
|
2012
|
0.83
|
|
10
|
Early diagnosis and successful treatment of a patient with transfusion-associated GVHD with autologous peripheral blood progenitor cell transplantation.
|
Transfusion
|
2002
|
0.82
|
|
11
|
Imaging and pharmacokinetics of (64)Cu-DOTA-HB22.7 administered by intravenous, intraperitoneal, or subcutaneous injection to mice bearing non-Hodgkin's lymphoma xenografts.
|
Mol Imaging Biol
|
2008
|
0.82
|
|
12
|
CD22 antigen is broadly expressed on lung cancer cells and is a target for antibody-based therapy.
|
Cancer Res
|
2012
|
0.81
|
|
13
|
Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT.
|
Clin Cancer Res
|
2003
|
0.80
|
|
14
|
Splenic volume change and nodal tumor response in non-Hodgkin's lymphoma patients after radioimmunotherapy using radiolabeled Lym-1 antibody.
|
Cancer Biother Radiopharm
|
2005
|
0.79
|
|
15
|
Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's lymphoma.
|
Oncoimmunology
|
2012
|
0.79
|
|
16
|
The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner.
|
J Hematol Oncol
|
2011
|
0.79
|
|
17
|
Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry.
|
J Nucl Med
|
2005
|
0.78
|
|
18
|
The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone.
|
Cancer Immunol Immunother
|
2011
|
0.76
|
|
19
|
Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer.
|
Int J Radiat Oncol Biol Phys
|
2006
|
0.75
|
|
20
|
Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma.
|
Cancer Biother Radiopharm
|
2007
|
0.75
|